Skip to main content Skip to search Skip to main navigation

EU: Parliament Votes to Revise MDR and IVDR

On 23 October, the European Parliament has adopted a resolution to revise the Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) to address ongoing implementation challenges and support patient access to essential medical devices by 2025.

Key elements of the resolution include:

  • Reducing Certification Bottlenecks: Streamlining certification processes and improving timelines and costs to ensure ongoing availability of critical medical devices and diagnostics.
  • Support for Innovation: Establishing an accelerated regulatory pathway for breakthrough and innovative medical technologies, particularly for orphan, pediatric, and other devices addressing unmet medical needs.
  • Enhanced tranparency and consistency across notofied bodies: Standardising assessment timelines, reducing administrative burdens, and improving consistency across notified bodies to aid manufacturers and increase market access predictability.
  • Support for SMEs: Prioritizing policies that help small and medium-sized enterprises (SMEs) navigate the regulatory landscape with fewer administrative challenges.
  • Improved Governance: Proposing a single governance structure to oversee the regulatory system, aiming for efficiency, sustainability, and improved patient outcomes.

Source:

EU: European Parliament resolution of 23 October 2024 on the urgent need to revise the Medical Devices Regulation (2024/2849(RSP))

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

With Commission Decision (EU) 2025/2371, the European Commission has formally declared that the first four EUDAMED modules meet the required functional specifications. Publication in the OJEU on 27 November 2025 activates the six-month transition period foreseen in Regulation (EU) 2024/1860.

Read more
Swissmedic: Digital Package Leaflet Instead of Paper

Swissmedic: Digital Package Leaflet Instead of Paper

From 1 December 2025, medicines intended solely for use by healthcare professionals no longer require a printed package leaflet. Instead, a QR code on the outer packaging must provide direct access to the professional information.

Read more
EMA: 6 New Nitrosamines for Appendix 1

EMA: 6 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.

Read more
How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
Previous
Next